Breast cancer is the most common cancer in women. Some forms are very aggressive due to their invasive growth and the high frequency of metastases. Treatment is extremely difficult and costly, especially when highly specific antibodies are applied. Two enzymes play a major role in the development of tumors HER2 and Brk. Enzyme inhibitors developed so far only inhibit HER2. The effectiveness is however limited since resistance has developed due to mutations in HER2. Novel substances are provided which selectively inhibit HER2 and/or Brk. The application of these substances allows addressing three important processes concurrently: the receptor mediated tumor growth, the inhibition of apoptosis, and metastasis.
Further information: PDF
ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
Phone: +49 (0)391/8 10 72 20
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
firstname.lastname@example.org | TechnologieAllianz e.V.
New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.
Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
16.08.2017 | Physics and Astronomy
16.08.2017 | Materials Sciences
16.08.2017 | Interdisciplinary Research